Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition READOUT: Deputy Undersecretary Lee visits Colombia, engages with new Petro administration leaders on labor compliance under trade agreement

Issued: London, UK

As part of its commitment to further transform the company’s approach to diseases that disproportionately affect the world’s poorest people, GlaxoSmithKline (GSK) today announced that it is creating a new operating unit dedicated to the Least Developed Countries (LDCs*).

A new Developing Countries and Market Access operating unit has been created which will integrate GSK’s pharmaceutical business in LDCs into one group. The group will provide a dedicated focus on the strategic approaches needed to expand access to medicines for patients living in these countries.

Andrew Witty, Chief Executive Officer, GSK, said, “Access to medicines continues to become hardwired into the way we do our business as we seek new solutions to challenges in all the communities in which we operate. Creating an operating unit specifically for the Least Developed Countries builds on our commitment to change the landscape of healthcare for the world’s poorest people.”

Duncan Learmouth is appointed to lead this new group, effective 1 August. He will report to Abbas Hussain, President, Emerging Markets/Asia Pacific. The new group will also include the Market Access function that supports access programmes and policies for the wider Emerging Markets and Asia Pacific (EMAP) Region.

Notes to editors

*As defined by the UN there are currently 49 Least Developed Countries (LDCs) of which 33 are in Africa. Structural weaknesses, poverty, susceptibility to natural and man-made disasters and to communicable diseases hamper the efforts of these countries to improve the quality of life of their people.
GSK recently reduced the prices of its patented medicines by an average of 45% in LDCs. The company is also reinvesting 20% of profits from medicines in LDC countries back into projects that strengthen healthcare infrastructure and help widen access to medicines.

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jen Hill Baxter

(215) 751 7002

Source link